Equities Analysts Issue Forecasts for KYMR FY2026 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Stock analysts at Brookline Capital Markets cut their FY2026 earnings per share estimates for Kymera Therapeutics in a report released on Thursday, October 29th. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn ($4.00) per share for the year, down from their previous estimate of ($3.97). Brookline Capital Markets currently has a “Buy” rating on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($3.90) per share. Brookline Capital Markets also issued estimates for Kymera Therapeutics’ Q4 2026 earnings at ($1.34) EPS, FY2027 earnings at ($5.16) EPS, FY2028 earnings at ($6.07) EPS, FY2029 earnings at ($5.48) EPS and FY2030 earnings at ($5.84) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. During the same quarter in the prior year, the firm earned ($0.94) EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company raised their target price on Kymera Therapeutics from $116.00 to $151.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Morgan Stanley upped their price target on shares of Kymera Therapeutics from $135.00 to $146.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 27th. Stifel Nicolaus upped their price target on shares of Kymera Therapeutics from $132.00 to $152.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. Mizuho increased their price objective on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $139.16.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $127.51 on Monday. The company has a market cap of $10.60 billion, a P/E ratio of -35.22 and a beta of 1.98. The stock has a fifty day moving average price of $115.08 and a 200 day moving average price of $96.61. Kymera Therapeutics has a 12 month low of $55.66 and a 12 month high of $130.05.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Mirae Asset Global Investments Co. Ltd. bought a new stake in Kymera Therapeutics during the third quarter worth approximately $514,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Kymera Therapeutics by 20.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 15,812 shares of the company’s stock valued at $1,747,000 after buying an additional 2,721 shares in the last quarter. Sterling Capital Management LLC increased its holdings in shares of Kymera Therapeutics by 378.6% in the third quarter. Sterling Capital Management LLC now owns 1,919 shares of the company’s stock valued at $215,000 after buying an additional 1,518 shares in the last quarter. Inspire Investing LLC acquired a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $482,000. Finally, Nisa Investment Advisors LLC lifted its position in shares of Kymera Therapeutics by 45.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,073 shares of the company’s stock valued at $232,000 after acquiring an additional 652 shares during the last quarter.

Insider Buying and Selling

In related news, insider Brian Adams sold 6,371 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the transaction, the insider owned 50,254 shares in the company, valued at $5,871,174.82. This trade represents a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. The trade was a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 15.98% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.